Results 71 to 80 of about 195,106 (347)

Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes

Arthritis Research & Therapy, 2018
Background The autoantibody profile of seropositive rheumatoid arthritis (RA) is very diverse and consists of various isotypes and antibodies to multiple post-translational modifications. It is yet unknown whether this varying breadth of the autoantibody
Emma C. de Moel, Veerle F. A. M. Derksen, Gerrie Stoeken, Leendert A. Trouw, Holger Bang, Robbert J. Goekoop, Irene Speyer, Tom W. J. Huizinga, Cornelia F. Allaart, René E. M. Toes, Diane van der Woude   +10 more
doaj   +1 more source

Distinct autoantibody profiles across checkpoint inhibitor types and toxicities [PDF]

Immune checkpoint inhibitors (ICI) are increasingly used in combination. To understand the effects of different ICI categories, we characterized changes in circulating autoantibodies in patients enrolled in the E4412 trial (NCT01896999) of brentuximab ...
Yang Xie, Kahl, Brad S, Fattah, F, Park, Jason Y, Zhu, C, Farjana Fattah, Wakeland, Edward K, Kahl, BS, Brad S. Kahl, Xie, Y, Hong Mu-Mosley, Jialiang Liu, Mitchell S. von Itzstein, Jason Y. Park, Fattah, Farjana, Park, JY, Catherine S. Diefenbach, Diefenbach, CS, von Itzstein, MS, Gerber, David E, Liu, Jialiang, Zhu, Chengsong, Chengsong Zhu, Edward K. Wakeland, von Itzstein, Mitchell S, Gerber, DE, Diefenbach, Catherine S, Xie, Yang, Liu, J, Mu-Mosley, Hong, Mu-Mosley, H, David E. Gerber, Wakeland, EK   +32 more
core   +1 more source

GAD65 Antibody ELISA With Extended Reportable Range: Validation and Guidance for Neurological Practice

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To (1) validate GAD65‐ELISA detection and quantification for type 1 diabetes mellitus and autoimmune neurological diagnoses, (2) correlate ELISA results (reference range < 5 IU/mL) with established radioimmunoprecipitation assay (RIA; ≤ 0.02 nmol/L), and (3) define ELISA clinical utility and pitfalls.
Andrew McKeon, Dana Olofson, Diana Anissian, Divyanshu Dubey, Eoin P. Flanagan, Max C. Herman, Sarosh R. Irani, Daniel H. Lachance, Maria A. Willrich, Sean Pittock, John R. Mills, Anastasia Zekeridou   +11 more
wiley   +1 more source

Islet autoantibodies as precision diagnostic tools to characterize heterogeneity in type 1 diabetes: a systematic review

Communications Medicine
Background Islet autoantibodies form the foundation for type 1 diabetes (T1D) diagnosis and staging, but heterogeneity exists in T1D development and presentation.
Jamie L. Felton, Maria J. Redondo, Richard A. Oram, Cate Speake, S. Alice Long, Suna Onengut-Gumuscu, Stephen S. Rich, Gabriela S. F. Monaco, Arianna Harris-Kawano, Dianna Perez, Zeb Saeed, Benjamin Hoag, Rashmi Jain, Carmella Evans-Molina, Linda A. DiMeglio, Heba M. Ismail, Dana Dabelea, Randi K. Johnson, Marzhan Urazbayeva, John M. Wentworth, Kurt J. Griffin, Emily K. Sims, On behalf of the ADA/EASD PMDI   +22 more
doaj   +1 more source

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

Late-Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor-Induced Raynaud's-Like Phenomenon

, 2020
The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press. Immune checkpoint inhibitor (ICI)-induced immune-related adverse events (irAEs) may affect almost any organ system and occur at any point during therapy.
Gerber, David E, Khan, Saad A, Lu, Rong, Li, Quan-Zhen, Khan, Shaheen, Park, Jason Y, Gloria-McCutchen, Yvonne, von Itzstein, Mitchell S, Karp, David R, Wakeland, Edward K, Xie, Yang, Bermas, Bonnie L, Saltarski, Jessica M, Fattah, Farjana J   +13 more
core   +1 more source

Differences and similarities of autoantibody-positive and autoantibody-negative rheumatoid arthritis during the disease course: on our way to personalized medicine [PDF]

, 2022
This thesis aims to assess the differences and similarities between autoantibody-positive and autoantibody-negative RA from the start of complaints to the end of the disease.
Matthijssen, X.M.E.
core  

Evaluation of Dried Plasma Spot‐Based Quantification of Glial Fibrillary Acidic Protein as a Disease‐Associated Biomarker in Neuromyelitis Optica Spectrum Disorder

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the diagnostic accuracy of glial fibrillary acidic protein (GFAP) measured in dried plasma spots versus conventional plasma‐ and serum‐GFAP testing for assessment of disease severity in aquaporin‐4 immunoglobulin G–positive neuromyelitis optica spectrum disorder (AQP4‐IgG+ NMOSD).
Felix Wohlrab, Evelyn Alvarez, Roua Hamdi, Bingqing Zhang, Hayeun Ji, Niyati Jhaveri, Patrick Schindler, Pedro Sanchez, Pia S. Sperber, Tanja Schmitz‐Hübsch, Frederike C. Oertel, Nisa Vorasoot, Najib Kissani, Falko Böhringer, Jens Kuhle, Anne‐Katrin Pröbstel, Xiao‐Jun Ma, Péter Körtvelyessy, Patrick Waters, Friedemann Paul   +19 more
wiley   +1 more source

Islet Autoantibody Standardization Program 2018 Workshop: Interlaboratory Comparison of Glutamic Acid Decarboxylase Autoantibody Assay Performance

Clinical Chemistry, 2019
BACKGROUND: The Islet Autoantibody Standardization Program (IASP) aims to improve the performance of immunoassays measuring type 1 diabetes (T1D)-associated autoantibodies and the concordance of results among laboratories.
V. Lampasona, D. Pittman, A. Williams, P. Achenbach, Michael Schlosser, B. Akolkar, W. Winter, K. Watson, I. Weets, Y. Tao, V. Chen, Y. Yang, R. Uibo, K. Reimand, M. Knip, T. Härkönen, L. Chatenoud, P. Achenbach, S. Neidhoefer, M. Schlosser, V. Lampasona, E. Kawasaki, M. Batstra, T. Cieremans, B. Almas, K. S. Opsion, K. Wyka, L. Castaño, A. Ramelius, I. Johansson, A. Williams, J. Furmaniak, T. Mcdonald, K. McLaughlin, M. Christie, A. Metz, A. Mathew, C. Hampe, C. Lu, C. Wasserfall, C. Mann, D. Pittman, J. S. Ananta, L. Yu, M. Mamula, P. Robinson, V. Gaur, W. Hagopian   +47 more
semanticscholar   +1 more source

Inebilizumab in AQP4‐Seropositive NMOSD: One‐Year Follow‐Up From a Multicenter, Real‐World Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Real‐world evidence on inebilizumab among neuromyelitis optica spectrum disorder (NMOSD) patients is lacking. This study assessed inebilizumab among Chinese patients with aquaporin 4 autoantibody (AQP4‐IgG)‐seropositive NMOSD in a real‐world setting.
Mengcui Gui, Jiayang Zhan, Wei Li, Tao Jin, Dan He, Daishi Tian, Zhijun Li, Jing Lin, Yue Li, Hongyu Zhou, Bitao Bu   +10 more
wiley   +1 more source